HSIE Results Daily 05 Nov 26 HSIE

The report notes EBITDA grew only 8% YoY despite 29% YoY sales growth due to higher operating costs, but maintains ADD citing steady India/US growth, R&D monetization and Medtech scale-up.

The report says BSE's revenue fell 8.5% QoQ due to CAS-related weakness in options activity but cost discipline aided margins, and maintains ADD with a raised target price.

The report notes strong Q2 topline and margin growth but maintains SELL citing heady valuations of ~80x Sep-28 EV/EBITDA.

The report states EBITDA declined 8% YoY despite 11% sales growth due to higher costs, but maintains ADD with a revised target price.

The report highlights strong Q2FY27 revenue/EBITDA growth as volumes recovered and maintains BUY with a raised EPS estimate.

The report notes EBITDA growth in line with estimates on gross margin expansion and reiterates ADD with a revised target price.

The report describes a mixed quarter with strong AUM growth offset by higher credit costs, maintaining ADD with a revised SoTP-based target price.

The report notes an EBITDA beat driven by volume and realization growth and reiterates BUY with a raised target price.

The report states profitability doubled on topline growth and improved underwriting, maintaining BUY despite flagging regulatory overhang from proposed commission reforms.

The report notes an EBITDA beat and raised growth/margin guidance from the company, maintaining ADD with a revised target price.

The report describes a mixed quarter with NIM reflation offset by moderating disbursement growth and higher delinquencies, maintaining ADD with an unchanged target.

The report notes in-line revenue growth but margin decline from cost pressures, maintaining REDUCE pending execution under the new CEO.

The report maintains SELL citing underutilized capex platforms and margin pressure from a methylamines supply glut and Chinese dumping, despite a Q2 beat.

The report notes in-line topline growth with muted SSSG due to festive timing shift and maintains ADD with unchanged estimates.

The report notes revenue growth led by exports and retains BUY with an unchanged target price despite margin contraction from freight and energy costs.

The report notes Prince Pipes' Q2 revenue grew 38% YoY led by strong plumbing volumes and NSR expansion, with EBITDA margin expansion (detail truncated in text).